Helsinki, Finland
Helsinki, Finland

Time filter

Source Type

News Article | May 4, 2017
Site: globenewswire.com

Biohit Oyj on globaaleilla markkinoilla toimiva suomalainen bioteknologiayritys. Biohitin missio on "Innovating for Health” - tuotamme innovatiivisia tuotteita ja palveluita edistämään tutkimusta ja varhaista diagnostiikkaa. Biohitin pääkonttori on Helsingissä, ja tytäryhtiöt sijaitsevat Italiassa ja Iso-Britanniassa. Biohitin B-sarjan osakkeet (BIOBV) noteerataan Nasdaq Helsingin Small cap/Terveydenhuolto-ryhmässä. www.biohit.fi


News Article | April 20, 2017
Site: globenewswire.com

TIEDOTE, 20. HUHTIKUUTA 2017 OSAKKEET BIOHIT OYJ: OPTIO-OIKEUKSILLA MERKITYT OSAKKEET Yhteensä 21 858 osaketta otetaan kaupankäynnin kohteeksi yhdessä vanhojen osakkeiden kanssa 21. huhtikuuta 2017. Biohit Oyj:n osakkeen perustiedot: Kaupankäyntitunnus: BIOBV ISIN-koodi: FI0009005482 id: 24241 Osakemäärä: 11 744 891 Nasdaq Helsinki Oy, Issuer Surveillance, survo@nasdaq.com, +358 9 6166 7260


News Article | April 20, 2017
Site: globenewswire.com

Biohit Oyj Total number of voting rights and capital April 20, 2017 at 9:30 am (EEST) A total number of 21 858 new Biohit Oyj B-shares have been subscribed for with stock options I 2013 B between 2 December 2016 and 9 March 2017. These shares have been entered into the trade register on April 20, 2017, as of which date the new shares will establish equal shareholder rights with the company's existing B-shares. Public trading is expected to begin on NASDAQ Helsinki as of April 21, 2017 together with the existing B-shares. The share subscription price was EUR 2.2766 per share respectively. The entire subscription price of EUR 49,761.93 will be credited to the reserve for invested non-restricted equity, and the company share capital remains unchanged. The shares have no nominal value. After the subscriptions the number of all Biohit Oyj's shares will rise to 14 720 391 shares and B-shares will rise to 11 744 891 shares. The share subscription period with stock options I 2013 B began on June 1, 2015 and will end on May 31, 2019. The option schemes are based on the Biohit Oyj board resolution of June 19, 2013 and the Annual General Meeting authorization of April 13, 2011. The terms and conditions of the option schemes with additional information are available on Biohit Oyj website at www.biohithealthcare.com . Biohit Oyj is a globally operating Finnish biotechnology company. Biohit mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com


News Article | May 4, 2017
Site: globenewswire.com

Biohit Oyj Changes board/management/ auditors May 4, 2017 at 10:00 a.m. local time (EEST) Lea Paloheimo, PhD (clinical biochemistry), has been appointed Biohit Oyj’s R&D and production director. Lea Paloheimo has been a member of the Biohit Oyj’s management team since 2006. CEO Semi Korpela, Biohit Oyj: ‘Lea Paloheimo has over fifteen years of experience in various positions in Biohit Oyj.’ Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com


News Article | April 26, 2017
Site: globenewswire.com

The Annual General Meeting (AGM) of Biohit Oyj held on Wednesday April 26, 2017 approved the financial statements of the parent company and the consolidated financial statements, and discharged the members of the Board of Directors and the President and CEO from liability for the financial year 2016. The AGM approved the Board of Directors proposal that no dividend shall be paid for the financial period ended on December 31, 2016. Members of the Board of Directors The AGM decided that the number of members of the Board of Directors would be five (5) and elected the following Board members until the end of the next AGM:  Professor (h.c.) Osmo Suovaniemi, CEO Franco Aiolfi, emeritus professor Matti Härkönen, professor Stina Syrjänen and Commercial Counsellor Eero Lehti. Additionally, the AGM decided that the Chairman of the Board of Directors would be paid a meeting fee of EUR 1,500 and the other Board members would be paid a meeting fee of EUR 1,500. Election and remuneration of the Auditor The AGM elected authorized public accountants PricewaterhouseCoopers Oy as the company’s auditor until the end of the next AGM. The auditor will be paid remuneration against the auditor’s invoice. All decisions of the AGM were made unanimously. The minutes of the AGM will be available for review by shareholders by May 2, 2017 on the company’s website (www.biohithealthcare.com /investors) and at the corporate headquarters of Biohit, located at Laippatie 1, 00880 Helsinki. Biohit Oyj is a globally operating Finnish biotechnology company. Biohit mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com


The present invention relates to a method for examining a person having the symptoms and/or biomarker indicating an autoimmune disease for the presence of atrophic gastritis. The biomarker combination, which diagnoses atrophic gastritis, acts also as a part of a biomarker panel that helps diagnosis and assessment of autoimmune disease as well. The invention relates also to products used in these methods.


Patent
Biohit Oyj | Date: 2013-05-28

The present invention concerns a non-toxic solid pharmaceutical composition for oral administration, containing one or more cysteine compounds from the group of L-cysteine, D-cysteine and N-acetyl cysteine, combined with one or more additional active agents, at least one of which being selected from cystine, glutathione and methionine, the composition further containing one or more pharmaceutical additives. Further, the invention concerns a method for reducing the incidence of severe headaches, particularly migraine and/or cluster headaches.


The present invention relates to non-toxic composition containing, as active compounds, one or more aldehyde-binding compounds, such as L- or D-cysteine, N-acetyl cysteine, and the pharmaceutically acceptable salts thereof, and optionally one or more further active compounds selected from sulphites and xylitol, the composition being used for decreasing the risk of a subject contracting cancer of the stomach, and indirectly of the small intestine and the large intestine. The composition is formulated into a controlled-release formulation consisting of granules contained in a capsule.


The present invention relates to a non-toxic composition containing one or more cysteine compounds selected from L- or D-cysteine, N-acetyl cysteine, and the pharmaceutically acceptable salts thereof, for decreasing the risk of a subject contracting cancer of the stomach, the small intestine and the colon, by locally binding aldehydes present in the stomach, and optionally also separately the aldehydes carried to the small intestine or the colon, or both, whereby the composition is formulated with the help of two or more additives into controlled-release tablets containing at least one additive selected from cationic and gel-forming polymers, which tablets are formed from two or more separate layers with different release profiles, whereby the cysteine compounds are added both into the inner layer(s) and into the tablet material surrounding these.


The present invention concerns products, such as compositions or medical devices, comprising one or more compounds of the Formula I, containing one or more free sulphhydryl groups,

Loading Biohit Oyj collaborators
Loading Biohit Oyj collaborators